The Resource Progress in cancer immunotherapy, Shuren Zhang, editor

Progress in cancer immunotherapy, Shuren Zhang, editor

Label
Progress in cancer immunotherapy
Title
Progress in cancer immunotherapy
Statement of responsibility
Shuren Zhang, editor
Contributor
Editor
Subject
Genre
Language
eng
Summary
This book provides readers an extensive overview of recent progress in basic and clinical research on cancer immunotherapy. Thanks to rapid advances in molecular biology and immunology, it has become increasingly evident that cancer growth is influenced by host immune responses. With the success of a number of clinical trials, immunotherapy has become a promising treatment modality of cancer. This book covers five major topics, including monoclonal antibodies, biological response modifiers, cancer vaccines, adoptive cellular therapy and oncolytic viruses. It also examines the combination of different immune strategies as well as the combination of immunotherapy with other treatments to increase anti-tumor effects. Through the comprehensive discussion of the topic, the book sheds valuable new light on the treatment of tumors
Member of
Cataloging source
N$T
Dewey number
616.99/406
Illustrations
illustrations
Index
no index present
LC call number
RC271.I45
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
  • W1
  • QZ 266
NLM item number
AD559 v.909 2016
http://library.link/vocab/relatedWorkOrContributorName
Zhang, Shuren
Series statement
Advances in experimental medicine and biology,
Series volume
volume 909
http://library.link/vocab/subjectName
Cancer
Label
Progress in cancer immunotherapy, Shuren Zhang, editor
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-94-017-7555-7
Instantiates
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Preface; Contents; Contributors; Chapter 1: Antibody Therapies in Cancer; 1 Historical Review of Antibody Therapeutics in Cancer; 1.1 Characteristics of Antibody; 1.2 Development of Antibody Therapies for Cancer; 1.3 Classes of Antibody Therapeutics in Cancer; 2 Tumor-Targeted Antibody Therapies; 2.1 An Outline of Tumor-Targeted Antibody Therapeutics; 2.1.1 Epidermal Growth Factor Receptor; 2.1.2 Human Epidermal Growth Factor Receptor; 2.1.3 VEGF; 2.1.4 Hematopoietic Differentiation Antigens; 2.1.4.1 CD20; 2.1.4.2 CD52; 2.1.4.3 CD19; 2.1.4.4 CD30
  • 2.2 Clinical Efficacy of Tumor-Targeted Antibody Therapeutics2.2.1 Hematological Malignancies; 2.3 Gastrointestinal Tumors; 2.3.1 Breast Cancer; 2.3.2 Lung Cancer; 2.3.3 Head and Neck Cancers; 2.3.4 Genitourinary; 2.4 Mechanisms Underlying the Antitumor Activity of Tumor-Targeted Antibodies; 2.4.1 Blockade of Ligand Binding and Signaling; 2.4.2 Antibody-Dependent Cellular Cytotoxicity and Phagocytosis; 2.4.3 Complement-Dependent Cytotoxicity; 2.4.4 Induction of T-Cell Immunity Through Cross-Presentation; 2.5 Immunoconjugates: Targeting Cytotoxic Agents to Tumor Cells
  • 2.5.1 Antibody-Drug Conjugates2.5.2 Radioimmunoconjugates; 3 Immunomodulating Antibody Therapies; 3.1 Therapy Targeting Immune Checkpoints in Cancer; 3.1.1 CTLA-4; 3.1.1.1 Biology of CTLA-4 Pathway; 3.1.1.2 Clinical Impact of CTLA-4 Blockade; 3.1.1.3 The Unique Kinetics of Responses to Ipilimumab; 3.1.1.4 The Biomarkers for Responses to Ipilimumab; 3.1.1.5 Side Effects of CTLA-4 Blockade; 3.1.2 PD-1; 3.1.2.1 Biology of PD-1 Pathway; 3.1.2.2 Expression of PD-1 and PD-L1 in Tumors; 3.1.2.3 Clinical Impact of Drugs Blocking PD-1; 3.1.2.4 Predictive Biomarkers for PD-1 Inhibitors
  • 3.1.2.5 The Side Effects of PD-1 Blockade3.1.2.6 Antitumor Mechanism of Checkpoint Blockade; 3.1.3 Other Potential Checkpoints; 3.1.3.1 LAG-3; 3.1.3.2 TIM-3; 3.1.3.3 B7-H3 and B7-H4; 3.1.3.4 Killer Inhibitory Receptors; 3.1.3.5 The Mechanisms of Evading Phagocytosis by Tumor Cells; 3.2 Immunostimulating Antibody Therapy; 3.2.1 TNFR Superfamily; 3.2.1.1 4-1BB; 3.2.1.2 OX40; 3.2.1.3 CD40; 3.2.2 Bispecific Antibodies; 3.2.3 Immunocytokines; 4 Combination Therapy of Antibodies; 4.1 Antibody Therapeutics in Combination with Conventional Therapies
  • 4.1.1 Combination of Tumor-Targeting Antibodies with Cytotoxic Chemotherapies4.1.2 Combination of Tumor-Targeting Antibodies with Radiation Therapy; 4.1.3 Combination of Immune Checkpoint Blockade with Conventional Therapies; 4.2 Antibody Therapeutics in Combination with Immunotherapies; 4.2.1 Combination of Multiple Checkpoint Blockades; 4.2.2 Combination of Checkpoint Blockade with Other Immunotherapies; 5 Future Prospects; References; Chapter 2: Biological Response Modifier in Cancer Immunotherapy; 1 Introduction; 2 Toll-Like Receptor Signaling and Agonists; 2.1 Toll-Like Receptors (TLRs)
Dimensions
unknown
Extent
1 online resource (xii, 283 pages)
File format
unknown
Form of item
online
Isbn
9789401775557
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
SpringerLink
Other control number
  • 10.1007/978-94-017-7555-7
  • 10.1007/978-94-017-7
Other physical details
illustrations (some color)
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)950971497
  • (OCoLC)ocn950971497
Label
Progress in cancer immunotherapy, Shuren Zhang, editor
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-94-017-7555-7
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Preface; Contents; Contributors; Chapter 1: Antibody Therapies in Cancer; 1 Historical Review of Antibody Therapeutics in Cancer; 1.1 Characteristics of Antibody; 1.2 Development of Antibody Therapies for Cancer; 1.3 Classes of Antibody Therapeutics in Cancer; 2 Tumor-Targeted Antibody Therapies; 2.1 An Outline of Tumor-Targeted Antibody Therapeutics; 2.1.1 Epidermal Growth Factor Receptor; 2.1.2 Human Epidermal Growth Factor Receptor; 2.1.3 VEGF; 2.1.4 Hematopoietic Differentiation Antigens; 2.1.4.1 CD20; 2.1.4.2 CD52; 2.1.4.3 CD19; 2.1.4.4 CD30
  • 2.2 Clinical Efficacy of Tumor-Targeted Antibody Therapeutics2.2.1 Hematological Malignancies; 2.3 Gastrointestinal Tumors; 2.3.1 Breast Cancer; 2.3.2 Lung Cancer; 2.3.3 Head and Neck Cancers; 2.3.4 Genitourinary; 2.4 Mechanisms Underlying the Antitumor Activity of Tumor-Targeted Antibodies; 2.4.1 Blockade of Ligand Binding and Signaling; 2.4.2 Antibody-Dependent Cellular Cytotoxicity and Phagocytosis; 2.4.3 Complement-Dependent Cytotoxicity; 2.4.4 Induction of T-Cell Immunity Through Cross-Presentation; 2.5 Immunoconjugates: Targeting Cytotoxic Agents to Tumor Cells
  • 2.5.1 Antibody-Drug Conjugates2.5.2 Radioimmunoconjugates; 3 Immunomodulating Antibody Therapies; 3.1 Therapy Targeting Immune Checkpoints in Cancer; 3.1.1 CTLA-4; 3.1.1.1 Biology of CTLA-4 Pathway; 3.1.1.2 Clinical Impact of CTLA-4 Blockade; 3.1.1.3 The Unique Kinetics of Responses to Ipilimumab; 3.1.1.4 The Biomarkers for Responses to Ipilimumab; 3.1.1.5 Side Effects of CTLA-4 Blockade; 3.1.2 PD-1; 3.1.2.1 Biology of PD-1 Pathway; 3.1.2.2 Expression of PD-1 and PD-L1 in Tumors; 3.1.2.3 Clinical Impact of Drugs Blocking PD-1; 3.1.2.4 Predictive Biomarkers for PD-1 Inhibitors
  • 3.1.2.5 The Side Effects of PD-1 Blockade3.1.2.6 Antitumor Mechanism of Checkpoint Blockade; 3.1.3 Other Potential Checkpoints; 3.1.3.1 LAG-3; 3.1.3.2 TIM-3; 3.1.3.3 B7-H3 and B7-H4; 3.1.3.4 Killer Inhibitory Receptors; 3.1.3.5 The Mechanisms of Evading Phagocytosis by Tumor Cells; 3.2 Immunostimulating Antibody Therapy; 3.2.1 TNFR Superfamily; 3.2.1.1 4-1BB; 3.2.1.2 OX40; 3.2.1.3 CD40; 3.2.2 Bispecific Antibodies; 3.2.3 Immunocytokines; 4 Combination Therapy of Antibodies; 4.1 Antibody Therapeutics in Combination with Conventional Therapies
  • 4.1.1 Combination of Tumor-Targeting Antibodies with Cytotoxic Chemotherapies4.1.2 Combination of Tumor-Targeting Antibodies with Radiation Therapy; 4.1.3 Combination of Immune Checkpoint Blockade with Conventional Therapies; 4.2 Antibody Therapeutics in Combination with Immunotherapies; 4.2.1 Combination of Multiple Checkpoint Blockades; 4.2.2 Combination of Checkpoint Blockade with Other Immunotherapies; 5 Future Prospects; References; Chapter 2: Biological Response Modifier in Cancer Immunotherapy; 1 Introduction; 2 Toll-Like Receptor Signaling and Agonists; 2.1 Toll-Like Receptors (TLRs)
Dimensions
unknown
Extent
1 online resource (xii, 283 pages)
File format
unknown
Form of item
online
Isbn
9789401775557
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
SpringerLink
Other control number
  • 10.1007/978-94-017-7555-7
  • 10.1007/978-94-017-7
Other physical details
illustrations (some color)
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)950971497
  • (OCoLC)ocn950971497

Library Locations

  • Architecture LibraryBorrow it
    Gould Hall 830 Van Vleet Oval Rm. 105, Norman, OK, 73019, US
    35.205706 -97.445050
  • Bizzell Memorial LibraryBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Boorstin CollectionBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Chinese Literature Translation ArchiveBorrow it
    401 W. Brooks St., RM 414, Norman, OK, 73019, US
    35.207487 -97.447906
  • Engineering LibraryBorrow it
    Felgar Hall 865 Asp Avenue, Rm. 222, Norman, OK, 73019, US
    35.205706 -97.445050
  • Fine Arts LibraryBorrow it
    Catlett Music Center 500 West Boyd Street, Rm. 20, Norman, OK, 73019, US
    35.210371 -97.448244
  • Harry W. Bass Business History CollectionBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • History of Science CollectionsBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • John and Mary Nichols Rare Books and Special CollectionsBorrow it
    401 W. Brooks St., Rm. 509NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • Library Service CenterBorrow it
    2601 Technology Place, Norman, OK, 73019, US
    35.185561 -97.398361
  • Price College Digital LibraryBorrow it
    Adams Hall 102 307 West Brooks St., Norman, OK, 73019, US
    35.210371 -97.448244
  • Western History CollectionsBorrow it
    Monnet Hall 630 Parrington Oval, Rm. 300, Norman, OK, 73019, US
    35.209584 -97.445414
Processing Feedback ...